Should we be utilizing prophylactic G-CSF in our patients with intermediate risk of febrile neutropenia due to the COVID-19 pandemic?  

Are you placing more weight on patient risk factors such as age >65 or co-morbidities?



profile picture
Jason Shohet, UMass Memorial Medical Center
Added May 22, 2020
2 people found this helpful
2 people agreed with this answer


profile picture
Robert Dreicer, University of Virginia
Added March 18, 2020
1 person found this helpful


theMednet is a knowledge-sharing community of 29,319 physicians
profile picture
profile picture
profile picture
profile picture
profile picture
profile picture
profile picture
profile picture
profile picture
profile picture
profile picture
profile picture
profile picture
profile picture
profile picture
profile picture
profile picture
profile picture
profile picture
profile picture